Enovis (NYSE:ENOV – Get Free Report) and MSP Recovery (NASDAQ:MSPR – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Institutional & Insider Ownership
98.4% of Enovis shares are held by institutional investors. Comparatively, 3.8% of MSP Recovery shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 50.5% of MSP Recovery shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Enovis and MSP Recovery, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 1 | 0 | 6 | 0 | 2.71 |
| MSP Recovery | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Enovis and MSP Recovery”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.23 billion | 0.74 | -$825.49 million | ($23.66) | -1.22 |
| MSP Recovery | $18.25 million | 0.03 | -$360.50 million | ($522.40) | 0.00 |
MSP Recovery has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enovis and MSP Recovery’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -37.80% | 6.78% | 3.73% |
| MSP Recovery | -7,328.48% | -326.80% | -81.27% |
Risk and Volatility
Enovis has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, MSP Recovery has a beta of -2.58, suggesting that its stock price is 358% less volatile than the S&P 500.
Summary
Enovis beats MSP Recovery on 11 of the 14 factors compared between the two stocks.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
About MSP Recovery
MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
